Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.50% | -27.80% | -6.23% | 17.21% | 5.49% |
| Total Depreciation and Amortization | -54.71% | 80.94% | 3.82% | 1.77% | 2.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.38% | 31.27% | 22.76% | 5.07% | 6.43% |
| Change in Net Operating Assets | -57.19% | 93.71% | 127.83% | -153.06% | -134.54% |
| Cash from Operations | -50.40% | -20.31% | 25.78% | 4.51% | -37.54% |
| Capital Expenditure | 64.96% | -74.52% | -528.00% | 89.13% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 72.26% | -74.52% | -528.00% | 89.13% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,733.33% | -95.03% | -99.62% | 169,003.57% | -22.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,733.33% | -95.03% | -99.62% | 17,571.96% | -852.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.74% | -22.83% | -136.90% | 286.03% | -42.15% |